Eli Lilly’s Cheaper Insulin Drug Is Second to Win FDA Approval

Americans living with diabetes have yet another option for insulin treatment after the Food and Drug Administration approved a second lower-cost product that acts nearly identical to the biologic drug.

The FDA on Monday gave the green light to Eli Lilly & Co.’s biosimilar Rezvoglar as part of the agency’s efforts to promote competition among insulin makers and ease access for patients. The approval means the drug has no clinically meaningful differences from Sanofi’s Lantus and can be prescribed to patients as an alternative.

The approval “furthers FDA’s longstanding commitment to support a competitive marketplace for insulin products,” the ...